Clinical Trials Logo

Clinical Trial Summary

Evaluating the Efficacy of Lapatinib in Combination With Chemotherapy in Patients With Trastuzumab-refractory Metastatic HER2-positive Breast Cancer.


Clinical Trial Description

Some studies has demonstrated that even in trastuzumab pretreated patients with HER-2 positive breast cancer, might benefit from the treatment of trastuzumab. However, there is small benefit for some patients having short disease-free survival after adjuvant trastuzumab or short progression-free survival after first-line trastuzumab-based therapy. In clinical practice, the investigators also found it is fact. And the investigators have a scientific rationale for clinical testing of lapatinib plus chemotherapy in patients with trastuzumab-refractory, metastatic HER2-positive breast cancer. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02362958
Study type Interventional
Source Sun Yat-sen University
Contact
Status Completed
Phase Phase 2
Start date January 9, 2015
Completion date May 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT01904903 - Cardiac Safety Study in Patients With HER2 + Breast Cancer Phase 2
Completed NCT02476539 - Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer Phase 1
Completed NCT01840306 - Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer
Completed NCT03735966 - Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients. Phase 2
Recruiting NCT01785420 - Pre Operative Trastuzumab in Operable Breast Cancer Phase 3
Recruiting NCT05132582 - A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Phase 3
Terminated NCT00817362 - Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer Phase 2
Not yet recruiting NCT03947242 - Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. N/A
Terminated NCT02213744 - MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients Phase 2/Phase 3
Completed NCT02614794 - A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer Phase 2
Completed NCT03013504 - A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients Phase 3
Completed NCT02682693 - Denosumab as an add-on Neoadjuvant Treatment (GeparX) Phase 2
Completed NCT02125344 - A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Phase 3
Active, not recruiting NCT04539938 - A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer Phase 2
Recruiting NCT05252988 - Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib Phase 2
Terminated NCT02963363 - Adapted Physical Activity for Breast Cancer HER2 Positive Patient N/A
Completed NCT02705859 - Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) Phase 1
Active, not recruiting NCT02993198 - A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging Phase 2